
Oncology NEWS International
- Oncology NEWS International Vol 15 No 3
- Volume 15
- Issue 3
Zactima Gets Fast Track Status for Medullary Thyroid Cancer
AstraZeneca, Zactima, ZD6474, medullary thyroid cancer
WILMINGTON, DelawareAstraZeneca's Zactima (ZD6474) has received FDA fast track designation for the treatment of medullary thyroid cancer. Zactima, a once-daily oral agent, targets tumor cells through inhibition of EGFR and REarranged during Transfection (RET) tyrosine kinases, and tumor blood supply through inhibition of VEGFR tyrosine kinase. Zactima, which also has orphan drug status for medullary thyroid cancer, is currently being evaluated in a phase II clinical trial.
Articles in this issue
about 20 years ago
FDA Approves Eraxis to Treat Candidemiaabout 20 years ago
NeoGuide's New Colonoscopy System Addresses ‘Looping'about 20 years ago
New Budget Plan Cuts NCI Funding by 0.8% for FY 2007about 20 years ago
Lilly Oncology on Canvas Invites Entriesabout 20 years ago
Shorter FEC + Pac Ups DFS in Breast Caabout 20 years ago
Xyotax Fast Tracked for Advanced NSCLC in Womenabout 20 years ago
FDA Guidances for Early Human Testing of New Drugsabout 20 years ago
Darbepoetin During RT Boosts Hb Level, With QOL Benefitabout 20 years ago
Breast, Colorectal Cancer Care Quality 'Excellent'about 20 years ago
Dose-Dense Adjuvant Chemo Validated in Breast CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.






















































